99552-78-0

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, α-broMo-2-Methoxy-, Methyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of complex organic molecules that can be further utilized in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, Benzeneacetic acid, α-broMo-2-Methoxy-, Methyl ester serves as an essential building block for the synthesis of various agrochemicals. Its properties make it suitable for the development of new pesticides, herbicides, and other agricultural chemicals.
Used as a Reagent in Organic Synthesis:
Benzeneacetic acid, α-broMo-2-Methoxy-, Methyl ester is used as a reagent in the synthesis of a wide range of organic compounds. Its versatility and reactivity make it an indispensable component in various chemical reactions, contributing to the formation of desired products in organic chemistry.

Upstream product

• 67-56-1 methanol 
• 251366-53-7 2-bromo-2-(methoxyphenyl)acetic acid 
• 135-02-4 ortho-anisaldehyde 
• 10408-29-4 o-methoxymandelic acid 
• 27798-60-3 methyl 2-(2-methoxyphenyl)acetate 
• 21165-11-7 methyl (+/-)-α-hydroxy-α-(2-methoxyphenyl)acetate 

Downstream Products

• 959682-13-4 {5-[2-(tert-butyldimethylsilanyloxy)ethyl]-imidazol-1-yl}-(2-methoxyphenyl)acetic acid methyl ester 
• 959682-15-6 {5-[2(4-fluorobenzylamino)ethyl]-imidazol-1-yl}-(2-methoxyphenyl)acetic acid methyl ester 
• 959682-16-7 [5-(2-methanesulfonyloxy-ethyl)-imidazol-1-yl]-(2-methoxyphenyl)acetic acid methyl ester 
• 959682-14-5 [5-(2-hydroxyethyl)-imidazol-1-yl]-(2-methoxyphenyl)acetic acid methyl ester 
• 1010445-84-7 tert-butyl 5-chloro-3-[methoxycarbonyl-(2-methoxyphenyl)methyl]-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate 
• 1010445-82-5 ethyl 3-[methoxycarbonyl-(2-methoxyphenyl)methyl]-2-oxo-2,3-dihydro-benzimidazole-1-carboxylate 

Relevant academic research and scientific papers

THIENO[2,3-C]PYRIDAZIN-4(1H)-ONE DERIVATIVE AND APPLICATION THEREOF

Disclosed are a thieno[2,3-c]pyridazin-4(1H)-one derivative as an ACC1 or ACC2 inhibitor and an application thereof in preparing a drug as an ACC1 or ACC2 inhibitor. In particular, disclosed is a compound represented by formula (II) or an isomer or pharma

Diastereo- And Enantioselective Synthesis of Quaternary α-Amino Acid Precursors by Copper-Catalyzed Propargylation

A diastereo- and enantioselective propargylic substitution reaction between propargylic carbonates and α-substituted nitroacetates catalyzed by a Cu-pybox complex is described. This method allows the preparation of a series of non-proteinogenic quaternary α-amino acid precursors featuring two contiguous stereogenic centers and a terminal alkyne moiety in high yields with good to excellent diastereo- and enantioselectivities in most cases. The propargylated adducts were elaborated into a diverse set of quaternary α-amino acid derivatives.

COMPOUNDS FOR OPTICALLY ACTIVE DEVICES

The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as tocompositions and ophthalmic devices comprising such compounds.

SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE

The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS

The present invention provides a compound of formula (I). Said compound is inhibitor of CYP11B2 and/or CYP11B1, and thus can be employed for the treatment of a disorder or disease mediated by CYP11B2 and/or CYP11B1.

Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives

The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ETA receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ETA antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC50 59 nM, rat aortic ET(A)). Optimization of 13a led to the identification of 27b, which exhibited an IC50 of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 μmol/kg) and was duly proposed and accepted as a development candidate.

Benzothiazine derivatives

Benzothiazine derivatives of the formula I STR1 with (R(1), R(1)', R(1)", R(4) and R(4)' equal to hydrogen, alkyl, alkoxy, halogen, nitro, hydroxyl, acetamido or amino; R(2) equal to hydrogen, alkyl, alkenyl, phenyl; R(3) equal to hydrogen, alkyl, alkenyl, phenyl; R(5) equal to hydrogen or (C1 -C3)-alkyl; R(6) equal to one of the following groups, STR2 with R(7) and R(8) equal to hydrogen, alkyl, cycloalkyl, phenyl; R(9) equal to hydrogen, alkyl, phenyl, pyridyl, pyrimidinyl or benzoyl; R(10) equal to hydrogen, alkyl, phenyl; R(11) equal to hydrogen, hydroxyl, alkoxy or, together with R(12), a bond; and R(12) equal to hydrogen or, together with R(11), a bond; m equal to 1, 2, 3 or 4; n equal to 0 or 1; p equal to 0, 1, 2, 3 or 4, and X equal to oxygen or two hydrogen atoms, and salts of the compounds of the formula I with physiologically tolerated acids and a process for the preparation of compounds I, likewise a method of treatment of disturbances of the calcium balance of a human body are described.